Arrowhead Pharmaceuticals (ARWR) - The company announced that dosing has begun in a new triple combination cohort utilizing JNJ-3989 plus additional undisclosed agents in the ongoing phase 1/2 study in patients with chronic hepatitis B virus. As a result of opening this new cohort, Arrowhead earned a $25 million milestone payment from its larger partner. The overarching goal here is to achieve higher rates of functional cure with a defined treatment duration in these chronic HBV patients. As can be imagined, the market is quite large for HBV with over 250 million people